April 12, 2024
Early data suggested that several new multicancer early detection (MCED) tests in development show promise for identifying cancers that lack routine screening options. Analyses presented during […]
April 12, 2024
SAN DIEGO — A new blood test that combines cell-free DNA fragmentomes and protein biomarkers to screen for ovarian cancer shows promising results, according to an […]
April 11, 2024
TOPLINE: New estimates show that patient enrollment in cancer clinical trials focused on treatments is about twice as high now compared with past estimates, with rates […]
April 11, 2024
Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These […]
April 11, 2024
SAN DIEGO — Using ImPrint, an immune-related biomarker, clinicians can identify patients with breast cancer who are likely to respond to neoadjuvant immunotherapy, according to data […]
April 10, 2024
San Diego — A liquid biopsy assay that combines a microRNA signature and a well-known biomarker for pancreatic cancer has demonstrated an accuracy of 97% for […]
April 10, 2024
SAN DIEGO — First-line treatment with a combination of cadonilimab, a PD-1/CTLA-4 bispecific immune checkpoint inhibitor, and standard chemotherapy provides a survival advantage over placebo plus […]
April 10, 2024
The results of a recently published study in eClinicalMedicine show that some of the so-called intermediate clinical endpoints (ICE) can predict changes in overall survival (OS) […]
April 8, 2024
The US Food and Drug Administration (FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with unresectable or metastatic HER2-positive […]